Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Primary Immunogenicity Objective: To evaluate homologous antibody responses to aH5N1 vaccine 3 weeks after second vaccination (day 43) according to CHMP immunogenicity criteria1 in adult (18 through 60 years of age) and elderly (≥61 years of age) subjects who are healthy or with underlying medical condition, as measured by hemagglutination inhibition (HI) assay. Primary Safety Objective: To evaluate in pooled age groups 18 years of age and older solicited and unsolicited adverse events in adults and elderly subjects who are healthy or with underlying medical condition who have received aTIV or aH5N1 vaccine.
Critère d'inclusion
- Pandemic influenza